Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium

April 15th 2025

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

April 14th 2025

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

April 11th 2025

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC

April 10th 2025

ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.

Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC

April 9th 2025

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

Dr Yu on Factors for PARP Inhibitor Decision-Making in Metastatic Prostate Cancer

April 8th 2025

Evan Ya-Wen Yu, MD, discusses considerations surrounding the tolerability of PARP inhibitors and how their adverse effect profiles influence treatment decisions in metastatic prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Dr Carles Galceran on the Safety of Darolutamide with ADT and Docetaxel in Older Patients With mHSPC

April 2nd 2025

Joan Carles Galceran, MD, PhD, discusses the safety of adding darolutamide to ADT and docetaxel in older patients with mHSPC.

Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease

April 2nd 2025

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Dr Morris on the FDA's Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mCRPC

April 2nd 2025

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Dr Dorff on the Safety of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC With Renal Impairment

April 1st 2025

Tanya B. Dorff, MD, highlights the safety profile of lutetium Lu 177 vipivotide tetraxetan in patients with mCRPC with impaired renal function.

The OncFive: Top Oncology Articles for the Week of 3/23

March 29th 2025

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

FDA Expands Indication for Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

March 28th 2025

The FDA has expanded the indication for lutetium Lu 177 vipivotide tetraxetan for use in additional patients with PSMA-positive metastatic castration-resistant prostate cancer.

Dr Morgans on PSA Doubling Time and Treatment Decisions in Biochemically Recurrent nmHSPC

March 25th 2025

Alicia Morgans, MD, MPH, discusses how a lack of PSA doubling time documentation may lead to undertreatment in high-risk BCR prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 3/16

March 22nd 2025

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Dr Bryce on the Comparative Efficacy of ARPIs Regardless of Disease Volume or Timing of Metastases in mHSPC

March 21st 2025

Alan H. Bryce, MD, discusses treatment comparisons of ARPI efficacy according to disease volume and timing of metastasis development in mHSPC.

FDA Approves PSMA PET Imaging Agent TLX007-CDx for Prostate Cancer

March 20th 2025

The FDA has approved TLX007-CDx as an imaging agent in select patients with prostate cancer.

PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC

March 20th 2025

Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.